Overview

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

Status:
Completed
Trial end date:
2014-07-02
Target enrollment:
Participant gender:
Summary
This study is conducted to assess the potential of topically-applied GSK2894512 cream at 3 concentrations (0.5%, 1%, and 2%) to induce skin irritation at the site of application in healthy subjects. Results from this study will be considered when selecting the concentration(s) of GSK2894512 to evaluate in the Phase II and Phase III clinical safety and efficacy studies. Approximately 40 subjects will be enrolled in order to have at least 30 evaluable subjects complete the study. The total duration of subject participation may be up to 50 days.
Phase:
Phase 1
Details
Lead Sponsor:
Stiefel, a GSK Company
Treatments:
Petrolatum